#Hong Kong #Immuno Cure #PharmaJet #ICVAX

Immuno Cure and PharmaJet's Innovative Collaboration on HIV Vaccine

In a groundbreaking partnership, Immuno Cure BioTech, a clinical-stage biotech company, has teamed up with PharmaJet to enhance HIV treatment through an innovative therapeutic DNA vaccine. The collaboration, announced during the BIO 2025 International Convention, revolves around the use of PharmaJet's needle-free injection technology to facilitate the delivery of ICVAX, an emerging HIV therapeutic vaccine.

Aiming for a Functional Cure

Despite significant advances in HIV treatment, including antiretroviral therapy (ART), the quest for a functional cure remains a dire global health challenge. Today, over 39 million individuals are living with HIV, highlighting the unmet medical need for more effective immunotherapies. ICVAX aims to address this need by utilizing Immuno Cure's patented PD-1-Enhanced DNA Vaccine technology. This approach could allow patients to achieve immune-mediated virological control without continuous ART.

Significance of the Collaboration

The partnership was solidified with a material transfer agreement (MTA) ceremony, underscoring a commitment towards innovative and safer patient care. Immuno Cure's CEO, Dr. Xia Jin, expressed enthusiasm about using PharmaJet's advanced Tropis device, which enables precise intradermal delivery without needles. This method is poised to improve patient compliance and treatment outcomes significantly.

PharmaJet’s Senior Vice President of Corporate Development, Mr. Dan Mallon, also highlighted the importance of their needle-free technology, believing it could transform the way HIV patients receive treatment by enhancing vaccine effectiveness and resulting in a more enjoyable patient experience.

Clinical Study Overview

This clinical study will be conducted at the renowned Prince of Wales Hospital in Hong Kong under the leadership of Professor Grace Lui from the Chinese University of Hong Kong. The project is a collaborative effort alongside the AIDS Institute at the University of Hong Kong and enjoys support from the Public Sector Trial Scheme of the Innovation and Technology Commission of the HKSAR Government. Professor Zhiwei Chen is steering the project coordination for this initiative.

With this collaborative effort, Immuno Cure and PharmaJet are expecting to lead a new era in vaccine delivery systems. Upon the successful completion of prior Phase I trials — which displayed promising safety and immunogenicity profiles for ICVAX — the study aims to evaluate the potential of the Tropis device to administer the vaccine effectively.

Benefits of Needle-Free Technology

The needle-free delivery offered by PharmaJet not only circumvents the discomfort associated with traditional injections but also promises to lower the risk of needlestick injuries, enhancing both safety and patient satisfaction. The Tropis system has gained regulatory clearances, further supporting its viability in clinical settings.

Future Prospects in HIV Management

As both companies aim to progress the global commercialization of ICVAX, they are setting their sights on transforming HIV patient management through cutting-edge technology. The collaboration reflects a shared vision — to address pressing health needs with innovative solutions that could change lives significantly.

By marrying vaccine technology with advanced delivery mechanisms, both Immuno Cure and PharmaJet are well-positioned to tackle the complexities of HIV treatment more effectively, providing hope to millions worldwide.

Summary

This innovative joint initiative symbolizes a promising step toward revolutionizing therapeutic strategies against HIV, bringing researchers, clinicians, and technology developers together to explore new avenues for patient treatment and care.